/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Related Keywords

Germany , New York , United States , Australia , Munich , Bayern , Perth , Western Australia , Russia , Adelaide , South Australia , Ukraine , Franziska Buri , Lawrence Steinman , Edna Kaplan , Heinz Wiendl , Thomas Polasek , Inge Kehler , Andreas Muehler , Hella Kohlhof , Paula Schwartz , Thomasm Polasek , Evelyn Peelen , Daniel Vitt , Juliano Fonseca , Jessica Breu , Jelena Mihajlovic , Jelena Mihajlovi , Fredd Lublin , Institute Of Translational Neurology , Department Of Neurology , University Of Mu , Stanford University School Of Medicine , Rx Communications Group , Prnewswire Immunic Inc , Nasdaq , Australasian Society Of Clinical , Department Of Neurology Neurological Sciences , Australasian Pharmaceutical Science Association , Corinne Goldsmith Dickinson Center , Neurological Sciences , Exchange Commission , Clinical Operations Program Lead At Immunic , Piper Sandler Co , Icahn School Of Medicine , Immunic Inc , Saunders Family Professor , Multiple Sclerosis , Icahn School , Mount Sinai Hospital , Stanford University School , Director Department , Translational Neurology , Piper Sandler , Annual Healthcare , Chief Executive Officer , Australasian Society , Experimental Pharmacologists , Clinical Pharmacology Registrar , Royal Adelaide Hospital , Tight Junction Regulator , Amelie Schreieck , Clinical Trials , Clinical Operations Program Lead , Clinical Operations , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Immunic , Nc ,